Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 9/20 | 0.46 |
| ▸ | KIT | P10721 | 6/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323214 | 0.94 | RET (0.54) | RETABL1KITDDR1FGFR1 | |
| SCHEMBL15907237 | 0.89 | ABL1 (0.51) | RETABL1KITFGFR1KDR | |
| SCHEMBL15907303 | 0.86 | KIT (0.46) | RETABL1KITDDR1FGFR1 | |
| SCHEMBL15907248 | 0.84 | ABL1 (0.48) | RETABL1KITDDR1FGFR1 | |
| SCHEMBL15907290 | 0.83 | ABL1 (0.46) | RETABL1KITFGFR1KDR | |
| SCHEMBL18323193 | 0.82 | ABL1 (0.58) | RETABL1KITFGFR1KDR | |
| SCHEMBL15907313 | 0.82 | KIT (0.44) | RETABL1KITDDR1FGFR1 | |
| SCHEMBL15907165 | 0.80 | KIT (0.57) | RETABL1KITFGFR1KDR | |
| SCHEMBL18323232 | 0.80 | RET (0.54) | RETABL1KITDDR1FGFR1 | |
| SCHEMBL15907275 | 0.79 | ABL1 (0.52) | RETABL1KITDDR1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | RET 45/4885ABL1 1/4885KIT 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.